Arrowhead Research (ARWR) stock

Genetic medicines , market cap $8.1B

Medicines for genetic diseases

Worth $8.1B

$48.49

-1.53%

As of 11:01 AM ET, delayed 15+ min · Live for Pro members

Why is ARWR down?

Down 15% on Nov 9 while the S&P 500 rose 2%.

Arrowhead Research fell 15% that day while pharma stocks rose a median 3%: it trailed its group by 18 points.

No SEC filing or news in our sources that day.

Sources: Price history, Nov 9, 2026

−1Long-term trend below a falling 200-day average

Tell me next time ARWR moves

Free account, no card. An optional alert when ARWR moves or its score changes.

Or see it live, free for 24 hours. No account.

1 more reason, free with an account →The timeline and its peers, for Pro members.

Quality Score

-3

Poor

In its industry

#77of 90

Pharma

Checks firing

1of 14

Trending down

From 52-week high

-49.2%

under its best in a year

ARWR's Quality Score fell 1 point on Mon, Nov 9, to -3. Its average daily range rose to 6.4%, with a $320M loss over four quarters and no positive free cash flow.

Follow ARWR's trial news. Pro members can get an alert when Arrowhead Research files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ARWR files news on its trialsSee it live, free for 24 hours. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“…the company intends to use with its upcoming plozasiran sNDA submission, anticipated before the end of 2026…”Filing with regulators · SEC filing · Aug 4

Cash$1.6B in cash. One of the last four quarters brought cash in while the others used it.On Jun 30

Key facts on ARWR

Key facts on ARWR
Holding it back	A $320M loss wider than $148M a year earlier
Latest filing	8-K, Nov 4 Took on new debt

1 more reason behind ARWR's -3, free with an account →2 more reasons behind ARWR's -3, for Pro members.

ARWR in the news

ReportReports Thursday, after the close. Every 3 months, a company tells everyone how much it sold and earned. It fell after 3 of its last 4 reports, +3.4% on average. Past reports ›

What's next

Wed Nov 18: Jefferies 17th Annual London Global…Investor conference · date confirmed.

2 more dates ahead: conferences, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$1.6B in cash. One of the last four quarters brought cash in while the others used it.On Jun 30

ARWR catalysts

Coming up

After its last 4 reports it closed +3.4% on average, higher 1 of 4 times.

4 more coming up and 15 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for ARWR, and how long its cash lasts

Next step the company has named

End of 2026“…review voucher, which the company intends to use with its upcoming plozasiran sNDA submission, anticipated before the end of 2026, to potentially expand the approved indication to include…”Filing with regulators · SEC filing · Aug 4

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

Lead program: Plozasiran · Hypertriglyceridemia · Phase 3
Its trial: SHASTA-10Phase 3 · Active · 710 people · main data estimated Jul 2028 · NCT06822790

11 more trials, 1 with data due this year, 32 filings, for Pro members.

Cash runway Jun 30 balance sheet

$1.6B in cash

One of the last four quarters brought cash in while the others used it, so an average says little about the next.

What it means: a runway is counted only when each of the last four quarters used cash.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Dec 11, 2025)
At-the-market share sales program (S-3ASR, filed Dec 11, 2025)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

Director Michael S Perry sold 11,600 shares on Aug 18. 8 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Christopher Anzalone buys or sells

For Pro members: every trade, and Christopher Anzalone’s 17 filings and quotes.

Get an alert when ARWR files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How ARWR ranks in Pharma

ARWR is #77 of 90 by Quality Score.

How ARWR ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	9/14	22
2	LLYEli Lilly	7/14	20
3	GMABGenmab	7/14	18
	ARDXArdelyx		Open for its score
	ARVNArvinas		Open for its score
	ASPEAspen Neuroscience		Open for its score
	AZNAstraZeneca		Open for its score
77	ARWRArrowhead Research	1/14	-3

Net income over four quarters: ARWR -$320M, RYTM -$194M, DYN -$605M.

When does ARWR report earnings, and what happens after?

Reports Thu Nov 12, after the close (in 2 days). Confirmed.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

Close after the report, last 3

-0.2%-6.8%-3.0%

Feb 5May 7Aug 4

Reported	When	Gap	Reaction	5 days
Aug 4, 2026After close	After close	-2.3%	-3.0%	-0.4%
May 7, 2026After close	After close	-1.9%	-6.8%	+2.2%
Feb 5, 2026After close	After close	+1.3%	-0.2%	-3.5%

ARWR closed higher after 1 of its last 4 reports.

All 4 reports, and ARWR's Quality Score going into each

Everyone reporting earnings this week

ARWR sales and profit by year

Sales and profit by year

Sales grew in four of the last seven years, to $829M in 2025. It made a profit in one of the eight years.

ARWR has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on ARWR, and all 14 on every stock.Get in free →

ARWR RSI today: 24.5, below its 50-day and 200-day averages

Not scored

RSI 24.5, MACD below signal, below both averages. Not scored.13 readings

The deep dive on ARWR

What it does and how it makes money2 findingsIt kept 12 cents of each dollar of sales in fiscal 2025: $98.3M of operating profit on $829M of sales.Annual report, filed Nov 25, 2025
Where it stands4 findingsFor Pro members4 findings on where ARWR stands: its cash, debt, and share count, for Pro members
What changed in its filings2 findings"On September 11, 2025, Ionis filed a Complaint for Patent Infringement against the Company in the United States District Court for the Central District of California alleging patent infringement of the ’333 patent by the Company’s planned commercialization of investigational plozasiran and seeking damages." (10-Q for the quarter to Jun 30, 2026)SEC filing · Aug 4, 2026A new heading in its "Risk Factors" this year: "If the FDA or comparable foreign regulatory authorities approve generic versions of REDEMPLO, or any other potential products that receive marketing approval …" (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Nov 25, 2025, against the one of Nov 26, 2024
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades ARWR, for Pro members
Against its closest peers3 peersNet income over four quarters: ARWR -$320M, RYTM -$194M, DYN -$605M.

8 more findings on ARWR, each with its source, for Pro members.

ARWR share count over time

Shares: 3.1% more than a year ago (to Jun 30).

Shares of ARWR outstanding, as filed
Shares outstanding	As of
141.3M	Jul 30, 2026
140.9M	May 1, 2026
140M	Jan 30, 2026
135.8M	Nov 19, 2025

Offerings, shelves, and splits of ARWR, from its filings
From its filings	Filed
Sold $75M of convertible notes	Jan 9, 2026
Sold $625M of convertible notes, about 8% of its market value	Jan 9, 2026
Registered shares for a later sale (S-3ASR)	Dec 11, 2025
Priced a sale of shares	Jan 4, 2024

ARWR insider trades

2 insiders sold $1.2M across 2 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellMichael S. Perry$1MDirectorat $87.30 on Aug 18, filed Aug 20

SellMichael S. PerryDirector$1Mat $87.30 on Aug 18, filed Aug 20

ARWR's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Christopher Richard AnzaloneChief Executive Officer · 20 trades
Daniel Joseph ApelChief Financial Officer · 1 trade
James C. HamiltonChief Medical Officer · 3 trades
Patrick O'BrienCOO · 1 trade
Adeoye Y. OlukotunDirector · 2 trades
Mauro FerrariDirector · 2 trades
Michael S. PerryDirector · 2 trades
William D. WaddillDirector · 1 trade

4 more officers and directors file at ARWR.

See insider trades by person

Which ETFs hold ARWR?

In ETFs: ARWR is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Arrowhead Research

Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.

711 employeesPasadena, CAarrowheadpharma.com

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on ARWR and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn ARWR's score around: 8 things
6 more filings explained, a plain line each
3 more things pulling ARWR's score down

BreakawayAug 20Michael S. Perry sold ARWR$1M at $87.30, filed Aug 20

Alerts are optional.

See ARWR's 14 chart checks

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: ARWR's Quality Score is -3 (Poor), #77 of 90 in Pharma. Insiders sold $1.2M in the last 6 months (Form 4).

What does ARWR's Quality Score say?

ARWR scores -3 today, which Breakaway calls Poor. It is #77 of 90 in Pharma by Quality Score, with 1 of 14 chart checks firing. Down 15% on Nov 9 while the S&P 500 rose 2%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ARWR's Quality Score?

ARWR scores -3 today, which Breakaway calls Poor (below zero). That is #77 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ARWR's -3.

Are insiders buying ARWR?

2 insiders sold $1.2M across 2 filings in the last 6 months. No open-⁠market buys on record. The newest is Michael S. Perry, Director, who sold $1M on Aug 18. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.